Newswire (Published: Tuesday, February 16, 2021, Received: Tuesday, February 16, 2021, 4:25:41 PM CST)
Word Count: 457
2021 FEB 16 (NewsRx) -- By a
The findings, published
The new study used data on almost 300,000 older men from two large, independent patient datasets--the Truven Health Analytics MarketScan database in
The findings build on previous preclinical research by the team, which showed that terazosin enhances cellular energy levels and can prevent or slow the progression of Parkinson’s disease in animal models. In this earlier study, the team also used the
Importantly, the researchers had a good control group for this earlier database study. Tamsulosin is another drug commonly used to treat enlarged prostate, but unlike terazosin, tamsulosin has no effect on cellular energy production, which the team’s lab studies suggest is important in terazosin’s protective effect.
The new study extends these findings to investigate whether terazosin, and related drugs that can also enhance cellular energy production, are associated with a reduced risk of developing Parkinson’s disease.
“We then tracked the health data on these men to determine how many in each group developed Parkinson’s disease,” explains
Additionally, the study found that longer duration of use of the energy-enhancing prostate drugs was associated with increased protective effects.
“Despite the relative differences in population and health care system structure, we found a similar protective effect in both countries,” Simmering adds. “The replication of the finding in an international cohort is powerful evidence suggesting a causal effect. If these results are confirmed through further investigation, especially a randomized clinical trial, terazosin may provide neuroprotection and potentially prevent--and not just manage--Parkinson’s disease.”
(Our reports deliver fact-based news of research and discoveries from around the world.)